Prof. Amnon Peled is an associate professor and the Director of the Gene Therapy Institute, Hadassah Medical Center, Jerusalem where he directs a laboratory, focusing on the role of cytokine in hematopoietic stem cell biology, inflammation, and cancer.
The laboratory of Prof. Peled's support the development of novel cell and molecular therapeutics for cancer and have been involved in the last 16 years in the development of novel therapies to cancer that are currently in Phase II and III.
Prof. Peled has authored or co-authored more than 100 publications and is listed as an inventor on over 200 patents related to therapeutic applications in stem cell biology, immunology, and cancer.
Prof. Peled worked in close collaboration with Israeli Biotechnology companies such as Biokine Therapeutics LTD, BiolineRX, Gamida Cell, Cellect Biotechnology Ltd., KAHR Medical Ltd. Ayala and others.
Prof. Peled is also the founder and CEO/CSO of Biokine Therapeutics. The company was founded in 2000 and is targeting tumor cell migration and proliferation.
Prof. Peled identified the CXCR4 chemokine receptor antagonist BKT140/BL8040 as a potent anti-cancer and stem cell mobilization agent and had supported the development of this drug candidate from bench through phase I and into Phase III.
Prof. Peled had a fundamental role in the development of cord blood stem cell and NK expansion technology of Gamida Cell Ltd and had supported the program since its initiation in 2006 through phase I/II and into Phase III clinical studies.
Prof. Peled has a Ph.D. from the Department of Cell Biology at the Weizmann Institute of Science and is experience includes time spent as a post Dr. at Harvard Medical School and Millennium Pharmaceuticals Inc.
Prof. Peled is a teacher and course coordinator: Cytokines and Chemokine Biology, other participants in the course from the GTI are Prof. Rachmilewitz, Prof. Reubinoff, Dr. Axelrod. In addition is a teacher in the course on advance topics in immunology